Clinical significance of metallothioneins in cell therapy and nanomedicine

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1477-1488

  Sharma, Sushil ^a   Rais, Afsha ^a   Sandhu, Ranbir ^a   Nel, Wynand ^a   Ebadi, Manuchair ^b  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

synuclein index; Charnoly body; Free radicals; Metallothioneins; Nanomedicine; Stem cells; Theranostics; Toxicity

Indexed keywords

ALPHA SYNUCLEIN; DACTINOMYCIN; DOMOIC ACID; ENVIRONMENTAL CHEMICAL; GOLD NANOPARTICLE; GROWTH HORMONE; INTERLEUKIN 10; LIPOSOME; METAL NANOPARTICLE; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN III; NEUROTROPHIC FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ZINC;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; BIOENERGY; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CELL DEGENERATION; CELL DIFFERENTIATION; CELL LABELING; CELL PROLIFERATION; CELL THERAPY; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; DEGENERATIVE DISEASE; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ELECTRON; FETUS CELL; HOMEOSTASIS; HUMAN; INFECTION; LEWY BODY; MESENCEPHALON; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NANOENCAPSULATION; NANOMEDICINE; NEURAL STEM CELL; NEUROPROTECTION; NITRATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

Α-SYNUCLEIN INDEX; CHARNOLY BODY; FREE RADICALS; METALLOTHIONEINS; NANOMEDICINE; STEM CELLS; THERANOSTICS; TOXICITY;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; METALLOTHIONEIN; NANOMEDICINE;

ANIMALIA; MAMMALIA;

EID: 84876495193     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S42019     Document Type: Review

References (84)

1. Marghoshes M, Vallee BL. A cadmium protein from equine kidney cortex. J Am Chem Soc. 1957;79:4813-4814.
2. Itoh M, Ebadi M, Swanson S. The presence of zinc-binding proteins in brain. J Neurochem. 1983;41(3):823-829.
3. Rupp H, Weser U. Conversion of metallothionein into Cuhionein, the possible low molecular weight form of neonatal hepatic mitochondrocuprein. FEBS Lett. 1974;44(3):293-297.
4. Vasak M, Galdes A, Hill HA, Kagi JH, Bremner I, Young BW. Investigation of the structure of metallothioneins by proton nuclear magnetic resonance spectroscopy. Biochemistry. 1980;19(3):416-425.
5. Vasak M, Kagi JH, Hill HA. Zinc(II), cadmium(II), and mercury(II) thiolate transitions in metallothionein. Biochemistry. 1981;20(10): 2852-2856.
6. Boulanger Y, Goodman CM, Forte CP, Fesik SW, Armitage IM. Model for mammalian metallothionein structure. Proc Natl Acad Sci U S A. 1983;80(6):1501-1505.
7. Braun W, Vasak M, Robbins AH, et al. Comparison of the NMR solution structure and the X-ray crystal structure of rat metallothionein-2. Proc Natl Acad of Sci U S A. 1992;89(21):10124-10128.
8. Zangger K, Oz G, Otvos JD, Armitage IM. Three-dimensional solution structure of mouse (Cd7)-metallothionein-1 by homonuclear and het-eronuclear NMR spectroscopy. Protein Sci. 1999;8(12):2630-2638.
9. Nielsen AE, Bohr A, Penkowa M. The balance between life and death of a cell: role of metallothioneins. Biomark Insights. 2007;1: 99-111.
10. Pastore A, Piemonte F. S-glutathionylation signaling in cell biology: progress and prospects. Eur J Pharm Sci. 2012;46(5):279-292.
11. Khatai L, Goessler W, Lorencova H, Zangger K. Modulation of nitric oxide-mediated metal release from metallothionein by the redox state of glutathione in vitro. Eur J Biochem. 2004;271(12):2408-2416.
12. Helal GK, Aleisa AM, Helal OK, et al. Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats. Oxid Med Cell Longev. 2009;2(1):26-35.
13. Min KS. Physiological significance of metallothionein in oxidative stress. Yakugaku Zasshi. 2007;127(4):695-702. Japanese [with English abstract].
14. Kooncumchoo P, Sharma S, Porter J, Govitrapong P, Ebadi M. Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci. 2006;28(2):125-141.
15. Nath R, Kambadur R, Gulati S, Paliwal VK, Sharma M. Molecular aspects, physiological function, and clinical significance of metallothioneins. Crit Rev Food Sci Nutr. 1988;27(1):41-85.
16. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron. 1991;7(2):337-347.
17. Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer. 2005;4:42.
18. Sharma SK, Ebadi M. Metallothionein attenuates 3-morpoholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid Redox Signal. 2003;5(3):251-264.
19. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal. 2003;5(3):319-335.
20. Ebadi M, Sharma S. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson's disease. Exp Biol Med (Maywood). 2006;231(9):1576-1583.
21. Ebadi M, Brown-Borg H, El Refaey H, et al. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Brain Res Mol Brain Res. 2005;134(1):67-75.
22. Ebadi M, Sharma S, Wanpen S, Shavali S. Metallothionein isoforms attenuate peroxynityrite-induced oxidative stress in Parkinson's disease. In: Ebadi M, Pfeiffer RF, editors. Parkinson's Disease. Boca Raton, FL: CRC Press; 2004:739-765.
23. Ebadi M, Sharma SK, Muralikrishnan D, et al. MTs provides ubiquinone-mediated neuroprotection in Parkinson's disease. Proc West Pharmacol Soc. 2002;45:36-38.
24. Ebadi M, Sharma SK, Ghafourifar P, Brown-Borg H, El Refaey H. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods Enzymol. 2005;396:276-298.
25. Sharma S, Ebadi M. Metallothioneins as early and sensitive biomarkers of redox signaling in neurodegenerative disorders. The IIOAB Journal. 2011;2(6):98-106.
26. Sharma S, Ebadi M. Therapeutic potential of metallothioneins as anti-inflammatory agents in polysubstance abuse. The IIOAB Journal. 2011;2(6):50-61.
27. Lee SJ, Koh JY. Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes. Mol Brain. 2010;3(1):30.
28. Sonn K, Pankratova S, Korshunova I, et al. A metallothionein mimetic peptide protects neurons against kainic acid-induced excitotoxicity. J Neurosci Res. 2010;88(5):1074-1082.
29. Dakshinamurti K, Sharma SK, Sundaram M, Watanabe T. Hippocampal changes in developing postnatal mice following intrauterine exposure to domoic acid. J Neurosci. 1993;13(10):4486-4495.
30. Gill SS, Hou Y, Ghane T, Pulido OM. Regional susceptibility to domoic acid in primary astrocyte cells cultured from the brain stem and hippocampus. Mar Drugs. 2008;6(1):25-38.
31. Pulido OM. Domoic acid toxicologic pathology: a review. Mar Drugs. 2008;6(2):180-219.
32. Rue E, Bruland K. Domoic acid binds iron and copper: a possible role for the toxin produced by the marine diatom Pseudo-nitzschia. Marine Chemistry. 2001;76:127-134.
33. Pedersen DS, Fredericia PM, Pedersen MO, et al. Metallic gold slows disease progression, reduces cell death and induces astrogliosis while simultaneously increasing stem cell responses in an EAE rat model of multiple sclerosis. Histochem Cell Biol. 2012;138(5):787-802.
34. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755-1761.
35. Lanza C, Morando S, Voci A, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem. 2009;110(5):1674-1684.
36. Mickova A, Buzgo M, Benada O, et al. Core/shell nanofibers with embedded liposomes as a drug delivery system. Biomacromolecules. 2012;13(4):952-962.
37. Chen XA, Zhang LJ, He ZJ, et al. Plasmid-encapsulated polyethylene glycol-grafted polyethylenimine nanoparticles for gene delivery into rat mesenchymal stem cells. Int J Nanomedicine. 2011;6:843-853.
38. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009;23(10):3361-3367.
39. Hofkens W, Grevers LC, Walgreen B, et al. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. J Control Release. 2011;152(3): 363-369.
40. Tang S, Liu Z, Zhao L, Zou Z, Du M. Transfection of pEGFP-C2 in brain mediated by targeting liposome P-MMA-DOSPER. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008;25(5):1170-1174. Chinese.
41. Giuliani AL, Wiener E, Lee MJ, Brown IN, Berti G, Wickramasinghe SN. Changes in murine bone marrow macrophages and erythroid burst-forming cells following the intravenous injection of liposome-encapsulated dichloromethylene diphosphonate (Cl2MDP). Eur J Haematol. 2001;66(4):221-229.
42. Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum Gene Ther. 1996;7(9):1111-1122.
43. Rahman YE, Hanson WR, Bharucha J, Ainsworth EJ, Jaroslow BN. Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Ann N Y Acad Sci. 1978;308:325-342.
44. Wang Y, Zeng B, Li X. Expression of human calcitonin by micro-encapsulated recombinant myoblasts. Biotechnol Lett. 2006;28(18): 1453-1458.
45. Xie Y, Ye L, Zhang X, et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J Control Release. 2005;105(1-2):106-119.
46. Hatakeyama H, Ito E, Yamamoto M, et al. A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. Mol Ther. 2011;19(8): 1487-1498.
47. Hatakeyama H, Akita H, Ito E, et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials. 2011;32(18):4306-4316.
48. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev. 2011;63(3):152-160.
49. Kawaguchi AT, Kametani Y, Kato S, Furuya H, Tamaoki K, Habu S. Effects of liposome-encapsulated hemoglobin on human immune system: evaluation in immunodeficient mice reconstituted with human cord blood stem cells. Artif Organs. 2009;33(2): 169-176.
50. Wong A. Modified epidermal growth factor receptor (EGFR)-bearing liposomes (MRBLs) are sensitive to EGF in solution. PLoS One. 2009;4(10):e7391.
51. Xiao Q, Xiao C. Preparation and characterization of silica-coated magnetic-fluorescent bifunctional microspheres. Nanoscale Res Lett. 2009;4(9):1078-1084.
52. Leung K. Quantum dot-prostate-specific membrane antigen antibody J591. In: Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD: National Center for Biotechnology Information; 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK23039/pdf/QD-PMSA.pdf. Accessed February 20, 2013.
53. Choi Y, Kim K, Hong S, Kim H, Kwon YJ, Song R. Intracellular protein target detection by quantum dots optimized for live cell imaging. Bioconjug Chem. 2011;22(8):1576-1586.
54. Lin CH, Chang LW, Chang H, et al. The chemical fate of the Cd/Se/Te-based quantum dot 705 in the biological system: toxicity implications. Nanotechnology. 2009;20(21):215101.
55. Chang CC, Sun KW, Lee SF, Kan LS. Self-assembled molecular magnets on patterned silicon substrates: bridging bio-molecules with nanoelectronics. Biomaterials. 2007;28(11):1941-1947.
56. Peyrot C, Gagnon C, Gagne F, Willkinson KJ, Turcotte P, Sauve S. Effects of cadmium telluride quantum dots on cadmium bioaccumulation and metallothionein production to the freshwater mussel, Elliptio complanata. Comp Biochem Physiol C Toxicol Pharmacol. 2009;150:246-251.
57. Wei L, Thakkar M, Chen Y, Ntim SA, Mitra S, Zhang X. Cytotoxicity effects of water dispersible oxidized multiwalled carbon nanotubes on marine alga, Dunaliella tertiolecta. Aquat Toxicol. 2010;100(2): 194-201.
58. Mounicou S, Ouerdane L, L'Azou B, et al. Identification of metallothionein subisoforms in HPLC using accurate mass and online sequencing by electrospray hybrid linear ion trap-orbital ion trap mass spectrometry. Anal Chemistry. 2010;82(16):6947-6957.
59. Neupane KP. Developing Metallothionein Capped Cadmium Selenide Nanoparticles [doctoral thesis]. Detroit, MI: Wayne State University; 2005.
60. Brenneman M, Sharma S, Harting M, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab. 2010;30(1):140-149.
61. Yang B, Strong R, Sharma S, et al. Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res. 2011;89(6):833-839.
62. Misra V, Yang B, Sharma S, Savitz S. Cell-based therapy for stroke. In: Cox CS, editor. Progenitor Cell Therapy for Neurological Injury. New York, NY: Humana Press; 2011:143-162.
63. Sharma S, Yang B, Strong R, et al. Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res. 2010;88(13):2869-2876.
64. Sharma S, Yang B, Xi X, Grotta J, Aronowski J, Savitz SI. IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res. 2011;1373:189-194.
65. El Khoury R, Misra V, Sharma S, et al. The effect of transcatheter injections on viability and cytokine release of mononuclear cells. AJNR Am J Neuroradiol. 2010;31(8):1488-1492.
66. Sharma S, Ebadi M. In vivo molecular imaging in Parkinson's disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M, editors. Parkinson's Disease, 2nd ed. Boca Raton, FL: CRC Press; 2013:787-802.
67. Liu Z, Ren G, Zhang T, Yang Z. Action potential changes associated with inhibitory effects on voltage-gated sodium currents of hippocampal CA1 neurons by silver nanoparticles. Toxicology. 2009;246(3):179-184.
68. Haase A, Rott S, Mantion A, et al. Effects of silver nanoparticles on primary mixed neural cell cultures: uptake, oxidative stress and acute calcium responses. Toxicol Sci. 2012;126(2):457-468.
69. Luther EM, Schmidt MM, Diendorf J, Epple M, Dringen R. Upregulation of metallothioneins after exposure of cultured primary astrocytes to silver nanoparticles. Neurochem Res. 2012;37(8):1639-1648.
70. Pan JF, Buffet PE, Poirier L, et al. Size dependent bioaccumulation and ecotoxicity of gold nanoparticles in an endobenthic invertebrate: the Tellinid clam Scrobicularia plana. Environ Pollut. 2012;168:37-43.
71. Pan Y, Leifert A, Graf M, et al. High-sensitivity real-time analysis of nanoparticle toxicity in green fluorescent protein-expressing zebrafish. Small. Epub 2012 Nov 12.
72. Fan J, Gallagher JW, Wu HJ, et al. Low molecular weight protein enrichment on mesoporous silica thin films for biomarker discovery. J Vis Exp. 2012;(62):3876.
73. Steenland K, Stayner L. Silica, asbestos, man-made mineral fibers, and cancer. Cancer Causes Control. 1997;8(3):491-503.
74. Bertoni-Freddari C, Fattoretti P, Casoli T, Di Stefano G, Giorgetti B, Balietti M. Brain aging: the zinc connection. Exp Gerontol. 2008;43(5): 389-393.
75. Mocchegiani E, Costarelli L, Giacconi R, Piacenza F, Basso A, Malavolta M. Micronutrient (Zn, Cu, Fe)-gene interactions in ageing and inflammatory age-related diseases: implications for treatments. Ageing Res Rev. 2012;11(2):297-319.
76. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semi-conductor quantum dots. Nano Lett. 2004;4(1):11-18.
77. Leigh K, Bouldin J, Buchanan R. Effects of exposure to semiconductor nanoparticles on aquatic organisms. J Toxicol. 2012;2012:397657.
78. Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J. 2006;273(9):1857-1870.
79. Penkowa M, Tio L, Giralt M, et al. Specificity and divergence in the neurobiologic effects of different metallothioneins after brain injury. J Neurosci Res. 2006;83(6):974-984.
80. Stankovic RK, Chung RS, Penkowa M. Metallothioneins I and II: neuroprotective significance during CNS pathology. Int J Biochem Cell Biol. 2007;39(3):484-489.
81. Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Agren MS. Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen. 2007;15(1):2-16.
82. Wong KK, Cheung SO, Huang L, et al. Further evidence of the anti-inflammatory effects of silver nanoparticles. Chem Med Chem. 2009;4(7):1129-1135.
83. Rajender G, Narayanan NG. Liquid chromatography-tandem mass spectrometry method for determination of sirolimus coated drug eluting nano porous carbon stents. Biomed Chromatogr. 2010;24(3): 329-334.
84. Karagkiozaki VC, Logothetidis SD, Kassavetis SN, Giannoglou GD. Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int J Nanomedicine. 2010;5:239-248.